Wednesday, July 8, 2026

pharma · Idiopathic Hypersomnia · Prader-Willi Syndrome · HRMY

Harmony Biosciences Holdings

Harmony Biosciences is a pharma organization headquartered in Plymouth Meeting, USA. It trades on NYSE under ticker HRMY. Primary therapeutic focus areas include Idiopathic Hypersomnia, Prader-Willi Syndrome, Hair Thinni

630 W. Germantown Pike, Suite 220, Plymouth Meeting, PA 19462, US HQ
2017 Founded
332 Employees
Public company Type
HRMY · NYSE Ticker
Company details
Status
Public
HQ
630 W. Germantown Pike, Suite 220, Plymouth Meeting, PA 19462, US
Founded
2017
Employees
332
Programs
21
Drugs
14
Patents
6
Clinical program

Pitolisant

Phase 3 · small molecule · Idiopathic Hypersomnia

Pitolisant for Idiopathic Hypersomnia is a Phase 3 program (small_molecule) at Harmony Biosciences Holdings with 1 ClinicalTrials.gov record(s).

← All Harmony Biosciences Holdings projects Phase 3 small molecule completed

Internal code HBS-101-CL-011

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Harmony Biosciences Holdings
Phase
Phase 3
Modality
small_molecule
Indication
Idiopathic Hypersomnia
Status
completed
Trials
1